LYON, France & NEWBURYPORT, Mass.—Novacap, a worldwide player in pharmaceutical synthesis and advanced specialties, announced in late June that it had completed the acquisition of PCI Synthesis. PCI Synthesis is a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of services, including process research and early-stage development as well as commercial production of new chemical entities, generic active pharmaceutical ingredients and other specialty chemical products.
The combination of the two companies will provide PCI Synthesis with additional resources to continue its development while reinforcing Novacap’s global leadership in pharmaceutical synthesis with 12 cGMP sites, two main R&D centers and its comprehensive range of services and technologies dedicated to clinical development and commercial manufacturing.
“Since we started the company more than 20 years ago, we’ve continued to evolve and innovate, and by teaming with Novacap, we will continue to do so, now with access to Novacap’s deep technical expertise to better serve our customers," said Ed Price, founder and president of PCI Synthesis.
“The acquisition of PCI Synthesis perfectly fits with our strategic roadmap, as it will strengthen our offerings to the pharmaceutical industry and provide Novacap with a strong and innovative platform to accelerate our development in the U.S. We have been impressed by the outstanding achievement of PCI Synthesis over the last years and its promising pipeline of projects. The two companies operate complementary CDMO activities and share common values such as entrepreneurship, operational excellence and dedication to customer satisfaction. We look forward to working with the PCI Synthesis team,” said Pierre Luzeau, CEO of Novacap.